JP2021504440A - ロキサデュスタット及びその中間体の調製方法 - Google Patents

ロキサデュスタット及びその中間体の調製方法 Download PDF

Info

Publication number
JP2021504440A
JP2021504440A JP2020529736A JP2020529736A JP2021504440A JP 2021504440 A JP2021504440 A JP 2021504440A JP 2020529736 A JP2020529736 A JP 2020529736A JP 2020529736 A JP2020529736 A JP 2020529736A JP 2021504440 A JP2021504440 A JP 2021504440A
Authority
JP
Japan
Prior art keywords
formula
compound
acid
alkyl
reaction mass
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020529736A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021504440A5 (enExample
Inventor
アマルナス レディ レッカラ
アマルナス レディ レッカラ
リラカール ジャイディープクマール ダヒャバイ
リラカール ジャイディープクマール ダヒャバイ
モハンマド アーシーフ
モハンマド アーシーフ
レハニ ラジーヴ ブドゥデヴ
レハニ ラジーヴ ブドゥデヴ
セカール ムナスワミー ナリヤム
セカール ムナスワミー ナリヤム
ラケシュワール バンディチョール
ラケシュワール バンディチョール
シャラッド サントゥ パチョア
シャラッド サントゥ パチョア
ソマ ラニ サルカール
ソマ ラニ サルカール
バブ イレニ
バブ イレニ
ディープ マラ
ディープ マラ
キラン クマール ドニパルティ
キラン クマール ドニパルティ
ベンカタ クリシュナ ラオ バダーラ
ベンカタ クリシュナ ラオ バダーラ
Original Assignee
ドクター レディズ ラボラトリーズ リミテッド
ドクター レディズ ラボラトリーズ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ドクター レディズ ラボラトリーズ リミテッド, ドクター レディズ ラボラトリーズ リミテッド filed Critical ドクター レディズ ラボラトリーズ リミテッド
Publication of JP2021504440A publication Critical patent/JP2021504440A/ja
Publication of JP2021504440A5 publication Critical patent/JP2021504440A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/21—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/08—Preparation of carboxylic acid esters by reacting carboxylic acids or symmetrical anhydrides with the hydroxy or O-metal group of organic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
JP2020529736A 2017-12-01 2018-11-30 ロキサデュスタット及びその中間体の調製方法 Pending JP2021504440A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN201741043126 2017-12-01
IN201741043126 2017-12-01
IN201841019627 2018-05-25
IN201841019627 2018-05-25
PCT/IB2018/059504 WO2019106621A1 (en) 2017-12-01 2018-11-30 Process for the preparation of roxadustat and its intermediates

Publications (2)

Publication Number Publication Date
JP2021504440A true JP2021504440A (ja) 2021-02-15
JP2021504440A5 JP2021504440A5 (enExample) 2022-01-06

Family

ID=66664380

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020529736A Pending JP2021504440A (ja) 2017-12-01 2018-11-30 ロキサデュスタット及びその中間体の調製方法

Country Status (8)

Country Link
US (1) US20200299242A1 (enExample)
EP (1) EP3717456A4 (enExample)
JP (1) JP2021504440A (enExample)
CN (1) CN111566090A (enExample)
BR (1) BR112020011040A2 (enExample)
CA (1) CA3083672A1 (enExample)
RU (1) RU2020121746A (enExample)
WO (1) WO2019106621A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2709493C1 (ru) * 2019-08-01 2019-12-18 Марат Феликсович Фазылов Способ получения роксадустата
WO2021026307A1 (en) 2019-08-07 2021-02-11 Teva Pharmaceuticals International Gmbh Processes for the preparation of roxadustat and intermediates thereof
CN115144480B (zh) * 2021-03-31 2023-11-28 成都倍特药业股份有限公司 一种从罗沙司他中间体中检测吗啉和/或四甲基甲烷二胺的方法
CN113248432B (zh) * 2021-04-25 2022-12-13 南京正济医药研究有限公司 高收率制备罗沙司他中间体的新方法
CN116903532A (zh) * 2023-06-02 2023-10-20 珠海优润医药科技有限公司 一种罗沙司他的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006527200A (ja) * 2003-06-06 2006-11-30 ファイブロゲン インコーポレイティッド 窒素含有ヘテロアリール化合物および内因性エリトロポエチンを増加させる際のそれらの使用方法
JP2014524920A (ja) * 2011-07-22 2014-09-25 ベイジン ベータ ファーマシューティカルズ カンパニー， リミテッド プロリルヒドロキシラーゼ阻害剤としての化合物の多形体、およびその使用
JP2015524409A (ja) * 2012-07-16 2015-08-24 フィブロジェン インコーポレイテッド イソキノリン化合物を作製する方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104892509B (zh) * 2015-06-04 2018-03-09 苏州明锐医药科技有限公司 诺得司他的制备方法
CN106478504B (zh) * 2016-09-29 2020-04-21 上海勋和医药科技有限公司 制备Roxadustat中间体的方法
CN108383787A (zh) * 2017-11-05 2018-08-10 王兆举 诺得司他的制备方法
CN108424388B (zh) * 2018-04-19 2020-08-21 杭州科巢生物科技有限公司 一种慢性贫血药物的制备方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006527200A (ja) * 2003-06-06 2006-11-30 ファイブロゲン インコーポレイティッド 窒素含有ヘテロアリール化合物および内因性エリトロポエチンを増加させる際のそれらの使用方法
JP2014524920A (ja) * 2011-07-22 2014-09-25 ベイジン ベータ ファーマシューティカルズ カンパニー， リミテッド プロリルヒドロキシラーゼ阻害剤としての化合物の多形体、およびその使用
JP2015524409A (ja) * 2012-07-16 2015-08-24 フィブロジェン インコーポレイテッド イソキノリン化合物を作製する方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
社団法人日本化学会, 新実験化学講座１４ 有機化合物の合成と反応Ｖ, JPN6022044589, 1978, pages 2535 - 2543, ISSN: 0005066589 *

Also Published As

Publication number Publication date
EP3717456A4 (en) 2021-09-15
CN111566090A (zh) 2020-08-21
RU2020121746A (ru) 2022-01-04
US20200299242A1 (en) 2020-09-24
EP3717456A1 (en) 2020-10-07
BR112020011040A2 (pt) 2020-11-17
CA3083672A1 (en) 2019-06-06
WO2019106621A1 (en) 2019-06-06

Similar Documents

Publication Publication Date Title
JP2021504440A (ja) ロキサデュスタット及びその中間体の調製方法
JP6181168B2 (ja) ある種の２−（ピリジン−３−イル）チアゾール類の製造方法
CN103497180B (zh) 4-（2,2-二氟-1,3-苯并二氧杂环戊烯-4-基）吡咯-3-腈的合成方法
US20200385355A1 (en) Method for synthesis of roxadustat and intermediate compounds thereof
CN114790151B (zh) 一种2-氰基-2-丙戊酸甲酯的复合催化制备方法
WO2016180033A1 (zh) 一种前列环素受体激动剂的制备方法
JP5102002B2 (ja) アセナピン合成中間体の製造方法
JP2018518489A (ja) アプレミラスト及びその中間体の調製方法
EP1497255A2 (fr) Procedes de preparation de combretastatines
US9376410B2 (en) (2R)-2-deoxy-2,2-disubstituted-ribono-1,4-lactone and preparation method and use thereof
BR112020004825B1 (pt) Processo aperfeiçoado para a preparação de trifloxistrobina
CN105968040B (zh) 一种雷迪帕韦中间体的制备方法
CN114763328A (zh) 一种2-氰基-2-丙戊酸的制备方法与应用
JP4022070B2 (ja) 新規チアゾール化合物およびその製造方法
JP6533798B2 (ja) ジヒドロイソオキサゾール誘導体の製造方法
CN102001920B (zh) 一种药物中间体的制备方法
WO1998057923A1 (en) New production process
TWI330642B (en) Method for producing triterpene
CN102020658B (zh) 2-氯-6，8-二氢-5H-咪唑[2，1-c]-[1，4]噁嗪及其制备方法
KR101463933B1 (ko) 5-치환된 또는 2,5-치환된 3-푸르알데히드 유도체의 제조방법
CN102020615B (zh) 一种吗啉酮衍生物及其制备方法
WO2016158716A1 (ja) ３－ハロゲン化アルキルピラゾール誘導体の製造方法
JP3855686B2 (ja) ３，３−ジアルコキシ−２−ヒドロキシイミノ誘導体及びその製造法
CN101160288A (zh) 烟酸衍生物或其盐的制造方法
JP5137576B2 (ja) １，２−ベンズイソキサゾール−３−酢酸のスルホン化法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211126

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211126

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221024

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20221020

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230525